WO1999006387A2 - O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents - Google Patents

O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents Download PDF

Info

Publication number
WO1999006387A2
WO1999006387A2 PCT/EP1998/004619 EP9804619W WO9906387A2 WO 1999006387 A2 WO1999006387 A2 WO 1999006387A2 EP 9804619 W EP9804619 W EP 9804619W WO 9906387 A2 WO9906387 A2 WO 9906387A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
integer
isopropylidenecumaran
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/004619
Other languages
French (fr)
Other versions
WO1999006387A3 (en
Inventor
Gianpiero De Cillis
Roberto Di Domenico
Bernhard Koenig
Ambrogio Oliva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP98943771A priority Critical patent/EP1012147B1/en
Priority to KR1020007000941A priority patent/KR100343067B1/en
Priority to CA002296476A priority patent/CA2296476A1/en
Priority to HR20000031A priority patent/HRP20000031A2/en
Priority to JP2000505146A priority patent/JP3241711B2/en
Priority to IL13419398A priority patent/IL134193A0/en
Priority to AT98943771T priority patent/ATE308535T1/en
Priority to HU0004221A priority patent/HUP0004221A2/en
Priority to DE69832184T priority patent/DE69832184D1/en
Priority to BR9811589-8A priority patent/BR9811589A/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to AU91559/98A priority patent/AU745839B2/en
Publication of WO1999006387A2 publication Critical patent/WO1999006387A2/en
Publication of WO1999006387A3 publication Critical patent/WO1999006387A3/en
Priority to NO20000366A priority patent/NO20000366D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the invention relates to de ⁇ vatives of 2-alkyhdene hydroxycumaranones wherein the hydroxy group is substituted by a mtrogen-contaming residue
  • These compounds possess uPA-uPAR antagonist activity and are useful as antitumor and/or antimetastatic agents.
  • uPA urokinase-type plasmmogen activator
  • ATF ammo-terminal fragment
  • aa 1-143 comprised of a growth factor-like domain (aa 4-43) and a k ⁇ ngle domain (aa 47-135).
  • uPA is a multifunctional protein involved m tissue proteolysis, cellular migration, cellular proliferation and growth factor activation uPA is released from cells as a virtually inactive pro-enzyme, pro-uPA
  • the activation of the single-chain pro-uPA by plasmin is regulated by tight control mechanisms which are not completely understood yet.
  • Most of the uPA activities are confined to the cell surface and the pe ⁇ cellular environment This is accomplished by binding to a specific, high-affinity receptor on the cell surface (uPAR). Both forms of uPA bind to uPAR with similar affinity The binding interaction is mediated by the growth factor-like domain [S.A. Rabbani et al , J Biol. Chem., 267, 14151-56, 1992].
  • the uPA receptor is a three domain glycoprotein where each t ⁇ phcated motif comp ⁇ zes a cysteme ⁇ ch consensus sequence of approximately 90 ammo acids [M. Plough et al., J Biol. Chem., 268, 17539-46, 1993].
  • uPAR is anchored to cell membrane by a glycosyl-phosphatidyhnositol moiety (GPI anchor)
  • GPI anchor glycosyl-phosphatidyhnositol moiety
  • uPAR binds uPA with D values between 10-10 and 10-9 M, depending on the expe ⁇ mental system.
  • uPAR The major determinants for uPA binding are located in the N-terminal domain 1 uPAR can be cleaved by uPA and plasmin, liberating a water soluble domain 1 and by the action of phospho pase C, three domains uPAR (1+2+3) can be released from the cell surface. This latter form of uPAR is also water soluble because the GPI-anchor is missing.
  • the inhibition of uPA dependent phenomena can p ⁇ ncipally be approached in two ways, either by direct inhibition of the proteolytic activity or by inhibition of uPA receptor binding.
  • the latter strategy has the potential of achieving greater specificity since inhibition might be localized to the pe ⁇ cellular environment.
  • uPA/uPAR system has been shown to be implicated in a va ⁇ ety of invasive biological processes such as tumor metastasis, trophoblast implantation, inflammation and angiogenesis. Therefore, uPAR antagonists block tumor invasiveness, metastasis and angiogenesis.
  • Formulations containing uPAR antagonists represent therapeutic treatments for a number of highly invasive and metastazising cancers where uPA and uPAR have been found to be consistently present at the invasive foci of the tumor [Dano et al., Proteolysis and Protein Turnover, eds. Barret + Bond, Portlan Press, 1994, London] (e.g. breast, lung, colon, ova ⁇ an cancers).
  • uPAR e.g. breast, lung, colon, ova ⁇ an cancers.
  • the amount of soluble uPAR appears to reflect the degree of proteolysis m the tumor and this might be closely related to patient prognosis.
  • Both uPA and uPAR levels m tumor tissue are prognostic factors in many types of cancers.
  • Inhibitors of plasmin generation by receptor bound uPA therefore have mechanism-based tumo ⁇ static, anti-invasive, anti-metastatic, anti- angiogemc, anti-arth ⁇ tic, anti-mflammatory, anti-osteoporotic, anti-retmopathic and contraceptive activities.
  • the invention relates the use of a compound of the formula (I):
  • R and R' are independently hydrogen, Q. 6 -alkyl, styryl or C 3 . 6 -cycloalkyl or, taken together with the carbon to which they are linked, form a C 3 . 6 -cycloalkyl group;
  • R 1 is hydrogen, methyl, ethyl, propyl, or isopropyl
  • R 2 is C ⁇ - 6 -alkyl, benzyl, phenyl, naphtyl or mdanyl, unsubstituted or substituted by chlo ⁇ ne, bromine, iodine, fluo ⁇ ne, C ⁇ . 6 - alkyl, hydroxy, ammo, carboxy, . 4 -alkoxy, C ⁇ -4-mono- or di-alkyl am o, C1.4- alkoxycarbonyl, mercapto, Cj 4 -alkylth ⁇ o, or
  • benzocondensed means that the heterocycle has two carbon atoms in common with a phenyl ⁇ ng.
  • 5- and 6-membered are thiophene, py ⁇ dine, and furane.
  • benzocondensed 5- and 6-membered heterocycles are lmidazole, quinolme, isoquinoline, indole, benzothiazole and benzoimidazole
  • the invention relates to a compound of formula I A
  • R ' (IA) wherein R, R', x, A, B, and T are as above, provided the compound of formula IA is not 4(3-(4-(4-fluorobenzam ⁇ do)p ⁇ pe ⁇ d ⁇ n)propoxy)-2- ⁇ sopropyhdencumaran-3-one.
  • x 1
  • B is the moiety N —
  • T is phenyl or phenyl substituted by one or two t ⁇ fluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
  • R and R' are Q. 6 -alkyl.
  • x is 1, and B is the moiety —
  • R and R' are methyl
  • x is 1
  • n is an integer from 2-6
  • q is an integer from 2 to 3
  • T is phenyl or phenyl substituted by one or two t ⁇ fluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
  • A is -(CH 2 ) n -, n is an integer from 2-6 and most preferably from 3-4, and T is phenyl or phenyl substituted by one or two t ⁇ fluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
  • R and R' are methyl
  • x is 1
  • B is the moiety —
  • T is phenyl or phenyl substituted by one or two t ⁇ fluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups
  • R and R' are methyl
  • x is 1
  • B is the moiety
  • A is -(CH 2 ) q -O-(CH 2 ) q - and q is an integer from 2 to 3
  • T is phenyl or phenyl substituted by one or two t ⁇ fluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
  • compositions containing a pharmacologically effective amount of a compound of formula (IA) with the exception of 4(3-(4-(4-fluorobenzam ⁇ do)p ⁇ pe ⁇ dm)propoxy)-2- ⁇ sopropyhdencumaran- 3-one in admixture with pharmaceutically acceptable excipients and/or diluents.
  • L-A-L' (IE) in which A has the above meanings and L, L' are leaving groups, which can be the same or different, and are preferably selected from chlo ⁇ ne, bromine, iodine, mesyl or tosyl groups, and an intermediate of formula (IV):
  • the intermediate product of the first synthesis step is preferentially isolated before submitting it to the second reaction.
  • the oxygen-alkylation is performed under strong basic conditions, preferably by means of an alkoxide of alkaline metal such as sodium ethoxide or isopropoxide, in a suitable solvent, preferably a (C ⁇ -4 )alkyl alcohol, and at temperatures ranging from 50°C to the boiling temperature of the solvent.
  • the mtrogen-alkylation is performed under milder conditions, in the presence of a base such as an organic base, preferably a t ⁇ alkylamme, or an inorganic base, preferably a carbonate of an alkaline or alkaline-earth metal, at temperatures ranging from room temperature to 50°C.
  • a base such as an organic base, preferably a t ⁇ alkylamme, or an inorganic base, preferably a carbonate of an alkaline or alkaline-earth metal, at temperatures ranging from room temperature to 50°C.
  • the intermediates of formula (III) are commercial products or can easily be prepared starting from commercial products by known methods such as halogenation of alcohols or their conversion into mesyl and tosyl de ⁇ vatives.
  • the mono-protected diamines of formula P-B-H and the compounds of formula (IV) are known commercial products or can be prepared from commercial products according to known methods.
  • IP incubation buffer
  • BIO-R4 solution 50 ng/well (0.5 (g/ml; 100 (1/well) in IP;
  • - uPAR solution 3 ng/well (30 ng/ml; 100 (1/well) in PBS-buffer (without Mg 2+ and Ca 2+ );
  • - blocking solution 1% skimmed milk powder in washing buffer (dissolved at 37°C);
  • testing substances are dissolved in DMSO. They are used in the test system with a highest concentration of 100 (g/ml. The solutions are prepared using PBS.
  • the invention also concerns pharmaceutical agents containing one or more compounds of formula (I).
  • the compounds of formula (I) are mixed in a known manner with suitable pharmaceutical earner substances, aromatics, flavou ⁇ ng and dyes and are formed for example into tablets or coated tablets or they are suspended or dissolved in water or an oil such as e.g. olive oil with addition of appropnate auxiliary substances.
  • the substance of the general formula (I) can be administered orally or parenterally in a liquid or solid form.
  • Water is preferably used as the medium which contains the stabilizing agents, solubihzers and/or buffers which are usually used for injection solutions.
  • Such additives are for example tartrate or borate buffers, ethanol, dimethylsulfoxide, complexing agents (such as ethylendiaminotetraacetic acid), high molecular polymers (such as liquid polyethylene oxide) for the regulation of the viscosity or polyethylene denvatives of sorbitol anhyd ⁇ des.
  • Solid earner substances are e.g. starch , lactose, mannitol, methylcellulose, talcum, highly dispersed silicic acid, higher molecular fatty acids (such as steanc acid), gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats or solid high molecular polymers (such as polyethylene glycols).
  • Suitable formulations for the oral route can if desired contain flavounngs and sweeteners.
  • the administered dose depends on the age, the health and the weight of the patient, the extent of the disease, the type of treatments which are possibly being earned out concurcently, the frequency of the treatment and the type of the desired effect.
  • the daily dose of the active compound is usually 0.1 to 50 mg/kg body weight. Normally 0.5 to 40 and preferably 1 to 20 mg/kg/day in one or several applications per day are effective in order to obtain the desired results.
  • the oily residue ( 24 g) was crystallized from 72 ml of hexane to give 11.26 g of the product, m.p. 79-82°C. A further 4 g of the product was obtained by chromatographic punfication (eluent chloroform/methanol 9 : 1) of the mother liquors of the crystallization.
  • a mixture of 4-hydroxycumaran-3-one (6.16 g), potassium hydroxide (6.16 g) and cyclohexanone (12 ml) in 75 ml of ethanol 96% was heated to 50°C for 2 hours, then the mixture was concentrated to dryness, 200 ml of water were added and the pH adjusted to pH 2 by the addition of hydrochloric acid (37%).
  • the mixture was extracted with methylene chloride (3 100 ml), the organic extracts pooled, washed with 100 ml of water, dried over sodium sulfate and concentrated to dryness.
  • a suspension of sodium metal (0.8 g) in 300 ml of anhydrous isopropanol was heated to 60°C until all of the sodium was solubihzed (about 2 hours 30 minutes), then 5.78 g of 4-hydroxy-2- ⁇ sopropyhdene cumaran-3-one (preparation 3) were added and the mixture was refluxed for 1 hour.
  • 3-[4-(4-fluorobenzam ⁇ do) p ⁇ pend ⁇ nyl]-l- chloropropane (10 g; example 1) was added and the reaction mixture refluxed for 3 hours, then kept at room temperature overnight.
  • the product was converted to the hydrochlonde by treatment of an ethanol solution with a 5.5 M solution of hydrogen chlonde in ethanol and precipitation from diethyl ether. M.p. of the hydrochlonde 235-238°C.
  • the reaction mixture was poured into water (150 ml), sodium chlonde was added and the mixture extracted with ethyl acetate (2x100 ml) The organic extracts were collected, -washed with bnne, dned over sodium sulfate and concentrated to dryness The residue (1.5 g) was punfied by silica gel chromatography (eluent. chloroform methanol 9 1), to give, after crystallization from diethyl ether hexane, 0.17 g of the product, m.p. 150-154°C.
  • a suspension of 0.11 g of sodium metal in 50 ml of dry isopropanol was heated at 60°C until all of the sodium had dissolved, then a solution of 4-hydroxy-2-(4'- heptylidene)cumaran-3-one (1.02 g; preparation 12) in 50 ml of dry isopropanol was added and the reaction mixture refluxed for 30 minutes. 1.77 g of 3-[4-(4- fluorobenzamido) piperidinyl]-l-chloropropane was then added. The mixture was heated to 80°C for 4 hours, then poured in 150 ml of aqueous saturated potassium carbonate solution and extracted with ethyl acetate.
  • reaction mixture was concentrated to a small volume, treated with ethyl acetate (200 ml) and the mixture washed with an aqueous saturated potassium carbonate solution. The organic phase was dned over sodium sulfate and concentrated to dryness. The residue (1.3 g) was crystallized from 10 ml of diethyl ether and dned under vacuum at 50°C, to give 1 06 g of the product, m p 220-225°C

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Compounds of formula (I) wherein R,R', A,B,T and x have the meaning given in the specification possess uPA (urokinase-type plasminogen activator) antagonist activity and can be employed as antitumor and/or antimetastatic agents.

Description

O-Substituted hvdroxycumaranone deπvatives as antitumor and antimetastatic agents
The invention relates to deπvatives of 2-alkyhdene hydroxycumaranones wherein the hydroxy group is substituted by a mtrogen-contaming residue These compounds possess uPA-uPAR antagonist activity and are useful as antitumor and/or antimetastatic agents.
The seπne proteases uPA (urokinase-type plasmmogen activator) catalyzes the activation of plasmmogen to plasmin which is involved in a variety of physiological and pathological processes. uPA is a multi-domain protein having a catalytic "B" chain (ammo-acids 144-411) and an ammo-terminal fragment ("ATF", aa 1-143) comprised of a growth factor-like domain (aa 4-43) and a kπngle domain (aa 47-135). uPA is a multifunctional protein involved m tissue proteolysis, cellular migration, cellular proliferation and growth factor activation uPA is released from cells as a virtually inactive pro-enzyme, pro-uPA The activation of the single-chain pro-uPA by plasmin (leading to the active two-chain form) is regulated by tight control mechanisms which are not completely understood yet. Most of the uPA activities are confined to the cell surface and the peπcellular environment This is accomplished by binding to a specific, high-affinity receptor on the cell surface (uPAR). Both forms of uPA bind to uPAR with similar affinity The binding interaction is mediated by the growth factor-like domain [S.A. Rabbani et al , J Biol. Chem., 267, 14151-56, 1992].
The uPA receptor is a three domain glycoprotein where each tπphcated motif compπzes a cysteme πch consensus sequence of approximately 90 ammo acids [M. Plough et al., J Biol. Chem., 268, 17539-46, 1993]. uPAR is anchored to cell membrane by a glycosyl-phosphatidyhnositol moiety (GPI anchor) uPAR binds uPA with D values between 10-10 and 10-9 M, depending on the expeπmental system. The major determinants for uPA binding are located in the N-terminal domain 1 uPAR can be cleaved by uPA and plasmin, liberating a water soluble domain 1 and by the action of phospho pase C, three domains uPAR (1+2+3) can be released from the cell surface. This latter form of uPAR is also water soluble because the GPI-anchor is missing.
The inhibition of uPA dependent phenomena can pπncipally be approached in two ways, either by direct inhibition of the proteolytic activity or by inhibition of uPA receptor binding. The latter strategy has the potential of achieving greater specificity since inhibition might be localized to the peπcellular environment.
Bacteπophage display technique and protein engmeeπng have recently been used to discover peptidic and species-specific uPAR antagonists [Goodson et al., PNAS, 91, 7129, 1994; Stratton-Thomas et al., Prot. Eng., 5, 463-470, 1995, respectively] The uPA/uPAR system has been shown to be implicated in a vaπety of invasive biological processes such as tumor metastasis, trophoblast implantation, inflammation and angiogenesis. Therefore, uPAR antagonists block tumor invasiveness, metastasis and angiogenesis. Formulations containing uPAR antagonists represent therapeutic treatments for a number of highly invasive and metastazising cancers where uPA and uPAR have been found to be consistently present at the invasive foci of the tumor [Dano et al., Proteolysis and Protein Turnover, eds. Barret + Bond, Portlan Press, 1994, London] (e.g. breast, lung, colon, ovaπan cancers). In patients with breast cancer and non-small cell lung cancer increased levels of uPAR in plasma have been detected. Therefore, the amount of soluble uPAR appears to reflect the degree of proteolysis m the tumor and this might be closely related to patient prognosis. Both uPA and uPAR levels m tumor tissue are prognostic factors in many types of cancers.
In addition to cancer, other diseases mediated by cell-surface activity of uPA are addressed by uPAR antagonists. Inhibitors of plasmin generation by receptor bound uPA therefore have mechanism-based tumoπstatic, anti-invasive, anti-metastatic, anti- angiogemc, anti-arthπtic, anti-mflammatory, anti-osteoporotic, anti-retmopathic and contraceptive activities.
We have now discovered that deπvatives of 2-alkylιdene hydroxycumaranones wherein the hydroxy group is substituted by a nitrogen-contam g residue have a significant activity of inhibition of the uPA/uPAR system functions by antagonizing the uPA receptor. These compounds are useful as antitumor and antimetastatic agents.
Some 6- and 4-pιpeπdιnoalkyloxy-2-alkyhdenecumaranones are disclosed in EP 0 088 986 as antihistaminic agents and as inhibitors of the anaphylactic shock. No antitumor or antimetastatic activity of those compounds has been reported so far.
In one aspect, the invention relates the use of a compound of the formula (I):
Figure imgf000004_0001
wherein:
R and R' are independently hydrogen, Q.6-alkyl, styryl or C3.6-cycloalkyl or, taken together with the carbon to which they are linked, form a C3.6-cycloalkyl group;
A is -(CH2)n-, -CH2CH=CHCH2-, -CH2-CH=CH-CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-, -CH2-CH2-CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-CH2- -CH2-CH2-CH=CH-CH2-CH2-, -CH2-CH2.CH2-CH=CH-CH2-, -CH2-CHOH-CHOH-CH2-, -(CH2)q-0-(CH2)q-, or -CH2-A'-Cϊi-, wherein q is an integer from 2 to 3 and n is an integer from 2 to 6, and A' is a .7-cycloalkyl group;
(I) -N(R1)-(CH2)m-N(R2)-, m which m is an integer from 2 to 6, R1 is hydrogen, methyl, ethyl, propyl, or isopropyl, and R2 is Cι-6-alkyl, benzyl, phenyl, naphtyl or mdanyl, unsubstituted or substituted by chloπne, bromine, iodine, fluoπne, Cι.6- alkyl, hydroxy, ammo, carboxy, .4-alkoxy, Cι-4-mono- or di-alkyl am o, C1.4- alkoxycarbonyl, mercapto, Cj 4-alkylthιo, or
Figure imgf000005_0001
Figure imgf000005_0002
T is -CH2-C≡CH, -C≡CH, -(CH2)P-R3, -CH=CH-R3, -CH2-NHCO-R3, -(CH2)P-O-R3 or -CH(NH2)-CH2RJ, in which p is 0 or an integer from 1 to 4, R3 is phenyl, naphthyl or biphenyl, unsubstituted or substituted by chloπne, bromine, iodine, fluoπne, (Cl- C6)alkyl, cyano, nitro, mono- or polyfluoroalkyl, -SQj(Cι-4)alkyl, -SO2NH2, -SO2NH(C,.4)alkyl, -SO2N[(C,.4)alkyl]2, -CONH2, -CONH(C1-4)alkyl, hydroxy, am o, carboxy, Cι. -alkoxy,
(Cι.4)mono- or di-alkyl ammo, (Cj 4)alkoxycarbonyl, mercapto, or Cj -alkylthιo, or is a 5- or 6-membered heterocycle which contains 1 or 2 heteroatom(s) selected from oxygen, sulfur or nitrogen and which is or is not benzocondensed, or a pharmaceutically acceptable salt of a compound of formula I in the manufacture of a medicament.for the treatment of tumors, particularly advanced solid tumors of breats, lung or colon, and metastases thereof.
The above formula I is understood to compπse enantiomers, diastereomers and racemates of the compounds of formula I and mixtures thereof which are also included within the scope of the present invention.
The term "benzocondensed" means that the heterocycle has two carbon atoms in common with a phenyl πng. Examples of 5- and 6-membered are thiophene, pyπdine, and furane. Examples of benzocondensed 5- and 6-membered heterocycles are lmidazole, quinolme, isoquinoline, indole, benzothiazole and benzoimidazole
In another aspect, the invention relates to a compound of formula I A
Figure imgf000006_0001
R ' (IA) wherein R, R', x, A, B, and T are as above, provided the compound of formula IA is not 4(3-(4-(4-fluorobenzamιdo)pιpeπdιn)propoxy)-2-ιsopropyhdencumaran-3-one.
Preferably, A is -(CH2)n-, -CH2CH=CHCH2-, or -(CH2)q-O-(CH2)q-, n is an integer from 2-6, and q is an integer from 2 to 3.
Preferably, x is 1
— N )— NH-
Preferably, B is the moiety N —
Preferably, T is phenyl or phenyl substituted by one or two tπfluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
Preferably, R and R' are Q.6-alkyl.
— N V— NH-
More preferably, x is 1, and B is the moiety —
Even more preferably, when R and R' are Q 6-alkyl, x is 1, and B is the
moiety
Figure imgf000006_0002
Even more preferably, when R and R' are C -alkyl, x is 1, and B is the
— N \— NH- moiety , A is -(CH2)n-, -CH2CH=CHCH2-, or -(CH2)q-O-(CH2)q-, n is an integer from 2-6, q is an integer from 2 to 3, and T is phenyl or phenyl substituted by one or two tπfluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
— N V- NH-
Preferably, when R and R' are methyl, x is 1, and B is the moiety - A is -(CH2)α-, -CH2CH=CHCH2-, or -(CH2)q-O-(CH2)q-, n is an integer from 2-6, q is an integer from 2 to 3, and T is phenyl or phenyl substituted by one or two tπfluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
Even more preferably, when R and R' are methyl, x is 1, and B is the
— N V- NH- moiety — A is -(CH2)n-, n is an integer from 2-6 and most preferably from 3-4, and T is phenyl or phenyl substituted by one or two tπfluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
— N V- NH-
Preferably, when R and R' are methyl, x is 1, and B is the moiety — A is -CH2CH=CHCH -, and T is phenyl or phenyl substituted by one or two tπfluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups
Preferably, when R and R' are methyl, x is 1, and B is the moiety
Figure imgf000007_0001
A is -(CH2)q-O-(CH2)q- and q is an integer from 2 to 3, and T is phenyl or phenyl substituted by one or two tπfluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
The most preferred compounds are:
4-(4-(4-(3,4-dιchlorobenzamιdo)pιpeπdιn-lyl)butoxy)-2-ιsopropylιdenecumaran-3- one,
(E)-4-(4-(4-(3,4-dιchlorobenzamιdo)pιpeπdιn-l-yl)-2-butenoxy)-2- ιsopropylιdenecumaran-3-one;
(Z)-4-(4-(4-(3 ,4-dιchlorobenzamιdo)pιpeπdm- 1 -y l)-2-butenoxy)-2- ιsopropylιdenecumaran-3-one;
4-(3-(4-(3-amιnosulfonyl-4-chlorobenzamιdo)pιpendιn-lyl)propoxy)-2- ιsopropylιdenecumaran-3-one;
4-[(2-(2-(4-(4-fluorobenzamιdo)pιpeπdιn-l-yl)ethyl)oxy)ethyloxy]-2- ιsopropylιdenecumaran-3-one.
Another object of the present invention are pharmaceutical compositions containing a pharmacologically effective amount of a compound of formula (IA) with the exception of 4(3-(4-(4-fluorobenzamιdo)pιpeπdm)propoxy)-2-ιsopropyhdencumaran- 3-one in admixture with pharmaceutically acceptable excipients and/or diluents.
Preparation of the compounds of the invention
The compounds of formula (I) can be prepared according to the two-step process descπbed in EP 088 986, which is herein incorporated by reference, which compπses reacting an intermediate of formula (II):
Figure imgf000007_0002
in which R and R' have the above meanings, an intermediate of formula (III):
L-A-L' (IE) in which A has the above meanings and L, L' are leaving groups, which can be the same or different, and are preferably selected from chloπne, bromine, iodine, mesyl or tosyl groups, and an intermediate of formula (IV):
H— B- ( IV)
(O) x in which B, T and x have the above meanings, said intermediates being reacted in two possible ways:
(1) reaction of a compound of formula (II) with a compound of formula (III), followed by reaction of the so obtained product with a compound of formula (IV), or alternatively reaction of a compound of formula (IV) with a compound of formula (III), followed by reaction of the so obtained product with a compound of formula (II)
In both cases the intermediate product of the first synthesis step is preferentially isolated before submitting it to the second reaction. In such a process m general the oxygen-alkylation is performed under strong basic conditions, preferably by means of an alkoxide of alkaline metal such as sodium ethoxide or isopropoxide, in a suitable solvent, preferably a (Cι-4)alkyl alcohol, and at temperatures ranging from 50°C to the boiling temperature of the solvent.
The mtrogen-alkylation is performed under milder conditions, in the presence of a base such as an organic base, preferably a tπalkylamme, or an inorganic base, preferably a carbonate of an alkaline or alkaline-earth metal, at temperatures ranging from room temperature to 50°C.
The intermediates of formula (II) can be obtained from the intermediates of formula (IT):
Figure imgf000008_0001
by reaction with an aldheyde or ketone of formula R-CO-R', in which R and R' are as above defined, in the presence of a base, preferably an hydroxide of an alkaline metal, in a solvent and at temperatures up to 100°C. A preferred reaction employs potassium hydroxide at reflux in ethanol. The compounds of formula (IF) are known and are descπbed in J. Am. Chem. Soc, 61, 2328 (1939), which is herein incorporated by reference.
The intermediates of formula (III) are commercial products or can easily be prepared starting from commercial products by known methods such as halogenation of alcohols or their conversion into mesyl and tosyl deπvatives.
The intermediates of formula (IV) can be prepared starting from a suitably mono- protected diamine of formula P-B-H, in which P is for example a benzyl or tert- butoxycarbonyl group, by acylation (if x=l) or alkylauon (if x=0) with a compound of formula (IV):
( IV )
(O) x in which L, T and x have the above meanings, preferably in the presence of a base and of an inert solvent and at temperatures ranging from 0°C to 50°C.
Alternatively, the compounds of formula (IV) in which x=0 can be obtained from the corresponding compounds with x=l by reduction of the amido group, for example with lithium aluminium hydπde.
The mono-protected diamines of formula P-B-H and the compounds of formula (IV) are known commercial products or can be prepared from commercial products according to known methods.
Biological activity of the compounds of the invention
Compounds of the invention were tested (ELISA test) as inhibitors of human urokinase (uPA) binding to its specific receptor uPAR mAk (BIO-R4), according to the procedure descπbed in Biol. Chem. Hoppe-Seyler, 376, 587-94 (1995) by Rettenberger et al.. The assays are performed in Microtiterplates (96 wells). The following solutions are used:
- washing buffer: PBS-buffer (without Mg2+ and Ca2+) + 0.05% Tween 20;
- incubation buffer (IP): 1% skimmed milk powder in PBS-buffer (without Mg2+ and Ca2+);
- BIO-R4 solution: 50 ng/well (0.5 (g/ml; 100 (1/well) in IP;
- uPAR solution: 3 ng/well (30 ng/ml; 100 (1/well) in PBS-buffer (without Mg2+ and Ca2+); - blocking solution: 1% skimmed milk powder in washing buffer (dissolved at 37°C);
- uPA solution: 0.25 ng well (5 ng ml; 50 (1/well) in IP. Detection solutions (per microtiterplate):
(1) 6 ml (100 mM Tπs-Cl pH 7.2 + 0.15% Tween 80) + 1.5 ml (10 (g) Plasm ogen in aqua bidest;
(2) 6 ml (100 mM Tπs-Cl pH 7.2 + 0.15% Tween 80) + 1.5 ml (7.5 mg) chromozyme PL in aqua bidest.
The detection solution must be contmously stirred. Testing substances: the testing substances are dissolved in DMSO. They are used in the test system with a highest concentration of 100 (g/ml. The solutions are prepared using PBS.
Three controls are performed: a) positive control: using 2% DMSO in PBS; b) negative control: assay without receptor; c) inhibition control:
1) inhibition (IC95 at 0.25 mg/ml) with dextranesulfate (MW = 500.000);
2) inhibition (IC90 at 1 (g/ml) with inactivated uPA (175 (g/ml)
Incubation is done as follows.
Each well is incubated by 100 (1 of BIO-R4 (c=0.5 (g/ml) for 1 hour at room temperature under shaking. After washing three times with the washing buffer, each well is incubated for 1 hour (37°C) with 200 (1/well blocking solution. After tπple washing each well is incubated for 1 hour at room temperature under shaking with 100 (1/well uPAR (c=30 ng/ml), then the wells are washed again three times with the washing buffer. The testing substance solution and the control solution, respectively, are added (50 (1 well) and are incubated for 30 minutes at room temperature under shabng. An additional 50 (1 of uPA solution (c=2.5 ng/ml) are added. After 1 hour at room temperature a tπple washing is performed.
For detection, the following procedure is used:
Incubation with 50 (1 each of detection solution (1) and (2) at room temperature. After 20 minutes a yellow colour will be visible (the positive control reads an extinction of 1 after 45-60 minutes) The detection is performed at 405 nm (reference is 490 nm) using a Dynatech MR 7000 ELISA reader To obtain the percentage of inhibition the following formula is used (E stands for extinction)-
% Inhibition = 100 - 100 X [Etest - Eneg. control / Epos- control " Eneg. control]
The data for representative compounds of the invention are shown below
Compound IC50 hie/m
4-(4-(4-(3 ,4-dιchlorobenzamιdo)pιpeπdιn- 1 -y l)butoxy )- 2-ιsopropylιdenecumaran-3-one >0.01
(E)-4-(4-(4-(3 ,4-dιchlorobenzamιdo)pιpeπdιn- 1 -y l)-2-butenoxy) -2-ιsopropyhdenecumaran-3-one >0.01
(Z)-4-(4-(4-(3,4-dιchlorobenzamιdo)pιpeπdm-l-yl)-2-butenoxy) -2-ιsopropylιdenecumaran-3-one >0.01
4-(3-(4-(3-ammosulfonyl-4-chlorobenzamιdo)pιpeπdm-lyl) propoxy)-2-ιsopropylιdenecumaran-3-one 0.05
4-[(2-(2-(4-(4-fluorobenzamιdo)pιpeπdm-l-yl)ethyl)oxy)ethyloxy]-2- ιsopropylιdenecumaran-3-one 0.05
The invention also concerns pharmaceutical agents containing one or more compounds of formula (I).
In order to produce pharmaceutical agents, the compounds of formula (I) are mixed in a known manner with suitable pharmaceutical earner substances, aromatics, flavouπng and dyes and are formed for example into tablets or coated tablets or they are suspended or dissolved in water or an oil such as e.g. olive oil with addition of appropnate auxiliary substances.
The substance of the general formula (I) can be administered orally or parenterally in a liquid or solid form. Water is preferably used as the medium which contains the stabilizing agents, solubihzers and/or buffers which are usually used for injection solutions. Such additives are for example tartrate or borate buffers, ethanol, dimethylsulfoxide, complexing agents (such as ethylendiaminotetraacetic acid), high molecular polymers (such as liquid polyethylene oxide) for the regulation of the viscosity or polyethylene denvatives of sorbitol anhydπdes.
Solid earner substances are e.g. starch , lactose, mannitol, methylcellulose, talcum, highly dispersed silicic acid, higher molecular fatty acids (such as steanc acid), gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats or solid high molecular polymers (such as polyethylene glycols). Suitable formulations for the oral route can if desired contain flavounngs and sweeteners. The administered dose depends on the age, the health and the weight of the patient, the extent of the disease, the type of treatments which are possibly being earned out concurcently, the frequency of the treatment and the type of the desired effect. The daily dose of the active compound is usually 0.1 to 50 mg/kg body weight. Normally 0.5 to 40 and preferably 1 to 20 mg/kg/day in one or several applications per day are effective in order to obtain the desired results.
The invention is illustrated further by the following non miting examples:
Preparation 1 • N-benzyl-4-(4-fluorobenzamιdo)pιpendme
A mixture of N-benzyl-4-amιnopιpendιne (30 g) and sodium bicarbonate (53 g) in 300 ml of dry methylene chloπde was cooled to 10°C. To this solution 23.24 ml of 4- fluorobenzoyl chlonde were added dropwise. After one hour at room temperature the reaction mixture was poured into 800 ml of water and extracted with chloroform (2x200 mi The organic extracts were collected, dned over sodium sulfate and concentrated to dryness. The residue (50 g) was treated with 300 ml of diethyl ether with stirnng for 2 hours, then filtered and dned under vacuum at 50°C to give 45.8 g of the product, m.p. 163-165°C.
Preparation 2 4-(4-fluorobenzamιdo)pιpeπdιne
To a solution of N-benzyl-4-(4-fluorobenzamιdo)pιpeπdιne (1 g) in 15 ml of dry methanol 0.2 g of palladium on charcoal followed by 1 g of ammonium formate were added. After 3 hours at room temperature the palladium on charcoal was filtered off and the mixture was concentrated to dryness. The residue was dissolved in water, brought to pH 9, and extracted with chloroform (3x20 ml). The organic extracts were collected, dned over sodium sulfate and concentrated to dryness to give 0 63 g of the product, m.p. 165-168°C.
Preparation 3 4-hydroxy-2-ιsopropylιdenecumaran-3-one
A mixture of 4-hydroxycumaran-3-one (35 g) and potassium hydroxide (86.3 g) in 863 ml of absolute ethanol and 120 ml of dry acetone was heated to 50°C for about 1 hour (until the suspension had completely dissolved). The reaction mixture was brought to pH 4.5 with 37% hydrochlonc acid, then concentrated to a small volume. The remaining suspension was poured into 1250 ml of water, stirced for 1 hour, filtered and dned under vacuum to give 38.8 g of the product, m.p 107-109°C.
Preparation 4 • N-tertbutoxycarbonyl-3-(4-fluorobenzamιdo)propylamιne
A mixture of N-tertbutoxycarbonyl-l,3-propylenedιamιne (1.74 g) in 17 ml of ethylacetate and 17 ml of saturated aqueous sodium bicarbonate solution was cooled to 0°C. To this mixture a solution of 1.31 ml of 4-fluorobenzoyl chlonde in 3 ml of ethyl acetate was added dropwise. The reaction mixture was kept at room temperature overnight, then poured into 50 ml of water. The organic layer was separated and the aqueous phase extracted with ethyl acetate. The organic extracts were collected, dned over sodium sulfate and concentrated to dryness. The residue was treated with 10 ml of hexane with stunng for 1 hour, then filtered and dned under vacuum at 50°C to give 2.84 of the product, m.p. 91-93°C.
Preparation 5 • 3-(4-fluorobenzamιdo)propylamme
A solution of N-tertbutoxycarbonyl-3-(4-fluorobenzamιdo)propylamιne (2.76 g; preparation 4) in 50 ml of dry methylene chlonde and 7.11 ml of tnfluoroacetic acid was stirred at room temperature overnight. The reaction mixture was then concentrated to dryness, redissolved in 50 ml of sodium bicarbonate solution and extracted with ethyl acetate (2x50 ml). Then the mother liquor was brought to pH 9.5, and after the addition of sodium chlonde extracted again with ethyl acetate (5x100 ml). The organic extracts were collected, washed with saturated aqueous solution of sodium chlonde (50 ml), dned over sodium sulfate and concentrated to dryness, to give 2.6 g of the product.
Preparation 6 N-benzyl-(4-tertbutoxycarbonylamιno)pιpendιne
A solution of N-benzyl-4-amιnopιpendιne (50 g) in 500 ml of tetrahydrofuran was cooled to 0°C. To this solution, a solution of ditert-butoxycarbonylether (65 g) in 65 ml of tetrahydrofuran was added dropwise. The resulting solution was concentrated to dryness, redissolved in 300 ml of chloroform and washed with 100 ml of bnne, then dned over sodium sulfate and concentrated to dryness. The residue (80 g) was suspended in 160 ml of hexane and stirred at room temperature for 1 hour to give after drying under vacuum at 50°C, 72.4 g of the product, m.p. 122-124°C.
Preparation 7 4-(tert-butoxycarbonylamιno)pιpendιne
A mixture of N-benzyl-(4-tertbutoxycarbonylamιno)pιpeπdιne (71 g), palladium on charcoal (7.1 g) and ammonium formate (78.6 g) in 1000 ml of dry methanol was stirced at room temperature overnight. The palladium on charcoal was then filtered off and the mixture concentrated to dryness and redissolved in 300 ml of water. The pH was adjusted to about 9 by the addition of 20% sodium hydroxide. The aqueous phase after the addition of sodium chlonde was extracted with ethyl acetate (3x100 ml). The organic extracts were pooled and dned over sodium sulfate and the solvent evaporated under reduced pressure. The residue (70 g) was suspended in 140 ml of hexane and stirced at room temperature for 1 hour to give, after drying under vacuum at 50°C, 48 g of the product, m.p. 150-152°C.
Preparation 8 - 3-r4-(tertbutoxycarbonylamιno)pιpendιn-l-yll-l-chloropropane
A mixture of (4-tertbutoxycarbonylamιno)pιpendιne (20 g) and potassium carbonate (20.7 g) in 200 ml of dry dimethylformamide was cooled to 0°C. A solution of 1- bromo-3-chloropropane (11.8 ml) in 11.8 ml of dimethylformamide was added dropwise thereto. The mixture was kept at room temperature overnight, then poured in 2000 ml of water and extracted with ethyl acetate (2x200 ml). The organic extracts were pooled, washed with 100 ml of bnne, dned over sodium sulfate and concentrated to dryness. The oily residue ( 24 g) was crystallized from 72 ml of hexane to give 11.26 g of the product, m.p. 79-82°C. A further 4 g of the product was obtained by chromatographic punfication (eluent chloroform/methanol 9 : 1) of the mother liquors of the crystallization.
Preparation 9 • 3-(4-amιnopιpeπdιn-l-yl)-l-chloropropane
1.35 ml of 8 N solution of hydrogen chlonde in ethanol was added to solution of 3-[4- (tertbutoxycarbonylammo)pιpeπdιn-l-yl]-l-chloropropane (0.5 g) in 5 ml of absolute ethanol. A precipitate quickly formed. After stirnng at room temperature overnight, the solid was collected by filtration and dned under vacuum at 40°C to give 0.4 g of the product, m.p. 266-268°C.
Preparation 10 N-benzyl-4-benzamιdopιpendιne
A mixture of N-benzyl-4-am opιpendιne (5 g) and sodium bicarbonate (8.83 g) in 50 ml of dry methylene chlonde was cooled to 10°C and 3.68 ml of benzoyl chlonde was added dropwise thereto. After 1 hour at room temperature, the reaction mixture was poured into 100 ml of water and extracted with methylene chlonde (2x100 ml). The organic extracts were pooled, dned over sodium sulfate and concentrated to dryness. The residue (10 g) was suspended in 200 ml of diethyl ether and stined at room temperature for 2 hours to give, after drying under vacuum, 6,92 g of the product, m.p. 168-171°C.
Preparation 11 • 4-benzamιdopιpeπdιne
A suspension of N-benzyl-4-benzamιdopιpendme (6.62 g; preparation 10) and palladium on charcoal (1 g) in 300 ml of dry methanol was hydrogenated at 49°C for 12 hours (about 750 ml of hydrogen were consumed), then the palladium on charcoal was filtered off. The solvent was evaporated under reduced pressure and the residue (5 g) is crystallized from 50 ml of diethyl ether and finally dned under vacuum at 50°C. 3.28 g of the product were obtained, m.p. 136-139°C.
Preparation 12 • 4-hydroxy-2-(4'-heptylιdene)cumaran-3-one
A mixture of 4-hydroxycumaran-3-one (1 g), potassium hydroxide (3.46 g) and 4- heptanone (6.64 ml) m 50 ml of absolute ethanol was heated to 40°C for 4 hours and at reflux for an additional 4 hours. The reaction mixture was concentrated to dryness, redissolved in 50 ml of water and the pH adjusted to about pH 4, then extracted with chloroform (2x50 ml). The organic extracts were pooled, dned over sodium sulfated and concentrated to dryness. The residue (1.8 g of a red oil) was punfied by silica gel chromatography (eluent hexane/ethyl acetate 5 : 1) to give 1.04 g of the product as a red oil. Preparation 13 N-benzyl-4-acetamιdopιpeπdιne
A mixture of N-benzyl-4-amιnopιpeπdme (5 g) and sodium bicarbonate (8.83 g) in 50 ml of dry methylene chlonde was cooled to 10°C. 2.32 ml of acetyl chlonde were added dropwise After 1 hour at room temperature, the mixture was poured into 100 ml of water and extracted with methylene chlonde (3x100 ml). The organic extracts were pooled, dned over sodium sulfate and concentrated to dryness to give, after crystallization from 30 ml of diethyl ether, 5.09 g of the product, m.p. 140-143°C.
Preparation 14 • 4-acetamιdopιpeπdιne
A mixture of N-benzyl-4-acetamιdopιpendme (4.89 g; preparation 13) and 0.3 g of palladium on charcoal m 150 ml of methanol was hydrogenated for 4 hours (about 600 ml of hydrogen were consumed), then the palladium on charcoal was filtered off. The reaction mixture was concentrated to dryness and the residue crystallized from 50 ml of diethyl ether to give 2.54 g of the product, m.p. 130-133°C.
Preparation 15 N-benzyl-4-heptanoylammopιpendιne
A mixture of N-benzyl-4-ammopιpeπdme (10 g) and sodium bicarbonate (17.65 g) in 50 ml of dry methylene chlonde was cooled to 10°C. Then, 9.85 ml of heptanoyl chlonde were added dropwise. The reaction mixture was kept at room temperature for 1 hour, then slowly added to 500 ml of water. The organic phase was separated and washed with 200 ml of water, dned over sodium sulfate and concentrated to dryness. The residue (15 g) was crystallized from 60 ml of diethyl ether to give 11.5 g of the product, m.p. 92-95°C.
Preparation 16 4-heptanoylamιnopιpeπdιne
A mixture of N-benzyl-4-heptanoylpιpeπdιne (11 g; preparation 15) and palladium on charcoal (0.55 ml) in 165 ml of dry methanol was hydrogenated at 50°C for about 3 hours 30 minutes (about 800 ml of hydrogen were consumed), then the catalyst was filtered off and the reaction mixture was concentrated to dryness, to give 7.6 g of the product, m.p. 75-77°C.
Preparation 17 4-hvdroxy-2-cyclopentylιdenecumaran-3-one
A mixture of 4-hydroxycumaran-3-one (1.5 g), potassium hydroxide (3.7 g) and cyclopentanone (6.24 ml) in 37 ml of absolute ethanol was heated to 40°C for 2 hours, then kept at room temperature overnight. The pH was then adjusted to pH 4 and the solvent evaporated under reduced pressure. 100 ml of water were added to the residue and the mixture extracted with ethyl acetate (2x50 ml). The organic extracts were pooled, dned over sodium sulfate and concentrated to dryness. The residue (10 g of a red oil) was treated with 50 ml of water to form a solid which was separated by decantation and treated again with 50 ml of water, then with 10 ml of ethanol The solid was finally recovered by filtration and dned under vacuum, to give, after recrystallization from 18 ml of hexane and purification by silica gel chromatography (eluent hexane/ethyl acetate 10 : 1), 0.89 g of the product.
Preparation 18 : N-benzyl-4-cvclohexylamidopiperidine
A mixture of N-benzyl-4-aminopiperidine (20 g) and sodium bicarbonate (35.3 g) in 200 ml of dry methylene chloride was cooled to 10°C. 17.2 ml of cyclohexanecarbonyl chloride were added dropwise. After 1 hour at room temperature, the reaction mixture was poured into 300 ml of water, the organic phase separated and washed with 100 ml of water, dried over sodium sulfate and concentrated to dryness. The residue (35 g) was crystallized from 200 ml of diethyl ether and dried under vacuum at 50°C, to give 26.6 g of the product, m.p. 150-152°C.
Preparation 19 : 4-cvclohexylamidopiperidine
A mixture of N-benzyl-4-cyclohexylamidopiperidine (20 g; preparation 18) and palladium on charcoal (1 g) in 300 ml of dry methanol was hydrogenated for 6 hours (about 2000 ml of hydrogen were consumed), then the catalyst was filtered off and the solvent was evaporated under reduced pressure. The residue (14 g) was crystallized from 60 ml of diethyl ether to give 12.7 g of the product, m.p. 174-176°C.
Preparation 20 : 4-hydroxy-2-cvclohexylidenecumaran-3-one
A mixture of 4-hydroxycumaran-3-one (6.16 g), potassium hydroxide (6.16 g) and cyclohexanone (12 ml) in 75 ml of ethanol 96% was heated to 50°C for 2 hours, then the mixture was concentrated to dryness, 200 ml of water were added and the pH adjusted to pH 2 by the addition of hydrochloric acid (37%). The mixture was extracted with methylene chloride (3 100 ml), the organic extracts pooled, washed with 100 ml of water, dried over sodium sulfate and concentrated to dryness. The residue (5 g of a red oil) was purified by silica gel chromatography (eluent methylene chloride/hexane 5 : 1) to give, after crystallization from 20 ml of hexane and drying under vacuum at 30°C, 1.72 g of the product, m.p. 117-120°C.
Example 1
3-r4-(4-fluorobenzamido) piperidinyll-1-chloropropane
A mixture of 10.65 g of 4-(4-fluorobenzamido)piperidine (preparation 2) and potassium carbonate (9.93 g) in 160 ml of dry dimethylformamide was cooled to 0°C and a solution of l-bromo-3-chloropropane (5.68 ml) in 5.68 ml of dry dimethylformamide added dropwise thereto. After 3 hours at room temperature the reaction mixture was poured into 1600 ml of water and stined for one hour. The solid which precipitated was recovered by filtration (7.1 g).
The mother liquors were extracted with ethyl acetate (2x100 ml), then adjusted to pH 9-10 and extracted again with chloroform (3x100 ml). The organic extracts were collected, dned over sodium sulfate and concentrated to dryness to give 5 g of a solid, which was added to the 7.1 g recovered before. The solid matenal was treated overnight with 50 ml of ethyl acetate with stirnng, filtered and dned under vacuum to give 4 g of the product.
Example 2
4-[3-(4-(4-fluorobenzamιdo)pιpeπdιn propoxyl-2-ιsopropyhdenecumaran-3-one
A suspension of sodium metal (0.8 g) in 300 ml of anhydrous isopropanol was heated to 60°C until all of the sodium was solubihzed (about 2 hours 30 minutes), then 5.78 g of 4-hydroxy-2-ιsopropyhdene cumaran-3-one (preparation 3) were added and the mixture was refluxed for 1 hour. 3-[4-(4-fluorobenzamιdo) pιpendιnyl]-l- chloropropane (10 g; example 1) was added and the reaction mixture refluxed for 3 hours, then kept at room temperature overnight.
The mixture was concentrated to a small volume (about 50 ml) then 1000 ml of water were added and the pH brought to 9. The resulting basic mixture was extracted with chloroform (3x300 ml) and the organic extracts collected, dned over sodium sulfate and concentrated to dryness. The residue of 13.8 g was treated with diethyl ether (138 ml) with stirnng and at reflux for 30 minutes, then filtered and punfied by silica gel chromatography (eluent chloroform methanol 9 : 1) to give 9.3 g of the product, m.p. 188-190°C.
The product was converted to the hydrochlonde by treatment of an ethanol solution with a 5.5 M solution of hydrogen chlonde in ethanol and precipitation from diethyl ether. M.p. of the hydrochlonde 235-238°C.
Example 3
4-(3-chloropropoxy)-2-ιsopropylιdenecumaran-3-one
A mixture of 4-hydroxy-2-ιsopropyhdenecumaran-3-one (19.2 g; preparation 3), potassium carbonate (13 95 g) and l-bromo-3-chloropropane (11.8 ml) m 250 ml of dry dimethylformamide was heated to 50°C for 3 hours, then the reaction mixture was poured into 2500 ml of water and extracted with chloroform (3x100 ml). The organic extracts were collected, washed with saturated aqueous solution of sodium chlonde (100 ml), dned over sodium sulfate and concentrated to dryness.
The residue (28 g) was punfied by silica gel chromatography (eluent methylene chlonde) to give, after drying under vacuum at 40°C, 19.36 g of the product, m.p. 78- 80°C. Example 4
4-r3-(3-(4-fluorobenzamιdo)propylamιno)propoxy]-2-ιsopropylιdenecumaran-3-one
A mixture of 4-(3-chloropropoxy)-2-ιsopropyhdenecumaran-3-one (1 69 g; example 3), 3-(4-fluorobenzamιdo)propylamιne (2 g; preparation 5) and potassium carbonate (0.88 g) in 50 ml of dry dimethylformamide was heated to 50°C overnight, then the reaction mixture was poured into 500 ml of water and extracted with ethyl acetate (3x100 ml) The organic extracts were collected, washed with 50 ml of water, dned over sodium sulfate and concentrated to dryness. The residue (3 g) was punfied by silica gel chromatography (eluent. chloroform/methanol 9 1) to give 0.11 g of the product
Example 5
4-(3-pιperazιnopropo\v)-2-ιsopropylιdenecumaran-3-one
A suspension of piperazme (5 47 g) in 42 ml of dry dimethylformamide was heated to 50°C until the solid had competely dissolved, then the reaction mixture was cooled to room temperature. 2.84 g of 4-(3-chloropropoxy)-2-ιsopropyhdenecumaran-3-one (example 3) were added. After 1 day of stirnng the mixture was poured into 420 ml of water and extracted with ethyl acetate (2x100 ml) and chloroform (2x100 ml), dned over sodium sulfate and concentrated to dryness.
The residue (3.3 g) was punfied by silica gel chromatography (eluenf chloroform/methanol/ammonium hydroxide 80 20 1), to give 2.87 of the product as
Example 6
4-r3-(4-(4-fluorobenzamιdo)pιperazm)propoxy1-2-ιsopropylιdenecumaran-3-one
A mixture of 4-(3-pιperazιnopropoxy)-2-ιsopropyhdenecumaran-3-one (0 318 g; example 5), 4-fluorobenzoyl chlonde (0.156 ml) and saturated aqueous sodium bicarbonate solution (5 ml) in 5 ml of dry methylene chlonde was stirred for 2 hours at room temperature. The organic phase was separated, dned over sodium sulfate and concentrated to dryness. The residue (0.47 g) was crystallized from diethyl ether/hexane to give 0 274 g of the product, m.p. 97-99°C.
Example 7
4-(4-chlorobutoxy)-2-ιsopropylιdenecumaran-3-one
A mixture of 4-hydroxy-2-ιsopropyhdenecumaran-3-one (0 56 g; preparation 3), 1- bromo-4-chlorobutane (0.41 ml) and potassium carbonate (0.4 g) in 10 ml of dry dimethylformamide was heated to 50°C for 3 hours. The reaction mixture was then poured into 100 ml of water and, after the addition of sodium chlonde, extracted with ethyl acetate (4x100 ml). The organic extracts were collected, dned over sodium sulfate and concentrated to dryness to give 0.75 g of the product as a dark red oil.
Example 8
4-r3-(4-(4-fluorobenzamιdo)pιpeπdιn)butoxy]-2-ιsopropylιdenecumaran-3-one
A mixture of 4-(4-chlorobutoxy)-2-ιsopropyhdenecumaran-3-one (0 7 g; example 7), potassium carbonate (0 34 g) and 4-(4-fluorobenzamιdo)pιpendme (0.72 g; preparation 2) in 10 ml of dimethylformamide was heated to 50°C for 3 hours, then a further 0.25 g of 4-(4-fluorobenzamιdo)pιpeπdme was added and stirnng continued at 50°C overnight.
The reaction mixture was poured into water (150 ml), sodium chlonde was added and the mixture extracted with ethyl acetate (2x100 ml) The organic extracts were collected, -washed with bnne, dned over sodium sulfate and concentrated to dryness The residue (1.5 g) was punfied by silica gel chromatography (eluent. chloroform methanol 9 1), to give, after crystallization from diethyl ether hexane, 0.17 g of the product, m.p. 150-154°C.
Example 9
3-f4-(4-methylbenzamιdo) pιpeπdιnyll-1-chloropropane
A mixture of 3-(4-ammopιpeπdιn-l-yl)-l-chloropropane (lg; preparation 9), sodium carbonate (0.42 g) and toluoyl chlonde (0 58 ml) in 20 ml of ethyl acetate and 20 ml of saturated aquoeus sodium bicarbonate solution was stmed at room temperature for 3 hour, then poured into 100 ml of water The organic phase was separated, dned over sodium sulfate and concentrated to dryness. The residue (1 4 g) was crystallized from 20 ml of hexane and the collected solid dned under vacuum at 50°C to give 1 05 g of the product, m.p. 150-152°C
Example 10
4-r3-(4-(4-methylbenzamιdo)pipendιnyl)propoxy]-2-ιsopropylιdenecumaran-3-one
A mixture of 4-hydroxy-2-ιsopropyhdenecumaran-3-one (0.61 g; preparation 3), 3-[4- (4-methylbenzamιdo) pιpendιnyl]-l-chloropropane (1.05 g; example 9) and potassium carbonate (0.44 g) in 15 ml of dry dimethylformamide was heated to 50°C overnight, then cooled to room temperature and poured into 100 ml of water. The aqueous phase was extracted with chloroform (3x100 ml), then the organic extracts were pooled and washed with 50 ml of bnne, dned over sodium sulfate and concentrated to dryness. The residue (7.5 g) was punfied by silica gel chromatography (eluent chloro form(methanol/tnethylamine 9 1 . 0.2) to give, after recrystal zation from 15 ml of diethylether/hexane and drying under vacuum at 50°C, 0 95 g of the product, m p. 198-202°C Example 11
3-(4-benzamidopiperidinyl)-l-chloropropane
A mixture of 4-benzamidopiperidine (3.2 g; preparation 11), triethylamine (5.67 ml) and l-bromo-3-chloropropane (2.31 ml) in 150 ml of tetrahydrofuran was refluxed overnight, then concentrated to a small volume and treated with 100 ml of chloroform. The solution was washed with 50 ml of aqueous saturated solution of potassium carbonate, dried over sodium sulfate and concentrated to dryness. The residue (6 g) was purified by silica gel chromatography (eluent chloroform/methanol 9 : 1) to give, after recrystallization from 20 ml of diethyl ether, 1.63 g of the product, m.p. 145- 147°C.
Example 12
4-F3-(4-benzamidopiperidinyl)propoxy]-2-isopropylidenecumaran-3-one
0.098 g of sodium metal was added to 50 ml of dry isopropanol and the mixture was kept at 60°C until all of the sodium had dissolved. The reaction mixture was then treated with 0.67 g of 4-hydroxy-2-isopropylidenecumaran-3-one (preparation 3), refluxed for 30 minutes then treated with 3-(4-benzamidopiperidinyl)-l-chloropropane (1.01 g; example 11) and again refluxed for a further 3 hours. The reaction mixture was concentrated to a small volume, treated with 100 ml of aqueous saturated potassium carbonate solution and extracted with ethyl acetate. The organic extracts were pooled, dried over sodium sulfate and concentrated to dryness. The residue (1.55 g) was purified by silica gel chromatography (eluent chloroform/methanol 15 : 1) to give, after recrystallization from ethyl acetate, 0.79 g of the product, m.p. 195-198°C.
Example 13
4-r3-(4-(4-fluorobenzamido)piperidinyl)propoxyl-2-(4'-heptylidene)cumaran-3-one
A suspension of 0.11 g of sodium metal in 50 ml of dry isopropanol was heated at 60°C until all of the sodium had dissolved, then a solution of 4-hydroxy-2-(4'- heptylidene)cumaran-3-one (1.02 g; preparation 12) in 50 ml of dry isopropanol was added and the reaction mixture refluxed for 30 minutes. 1.77 g of 3-[4-(4- fluorobenzamido) piperidinyl]-l-chloropropane was then added. The mixture was heated to 80°C for 4 hours, then poured in 150 ml of aqueous saturated potassium carbonate solution and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated to dryness to give 2.3 g of an oily residue which was purified by silica gel column chromatography (eluent chloroform/methanol 9 : 2). After recrystallization from 20 ml of diethyl ether, 1.12 g of the product are obtained, m.p. 140-143°C. Example 14
2-l r4-(4-fluorobenzamιdo) pιpeπdιnyll-1-chloroethane
A mixture of 4-(4-fluorobenzamιdo)pιpeπdιne (2 g; preparation 2), tnethylamine (3 75 ml) and l-bromo-2-chloroethane (1 11 ml) in 150 ml of dry tetrahydrofuran was refluxed overnight, then further tnethylamine (3 75 ml) and l-bromo-2-chloroethane (1 11 ml) were added. The mixture was refluxed for an additional 5 hours, treated again with 3 75 ml of tnethylamine and 1.11 ml of l-bromo-2-chloroethane and refluxed overnight. The reaction mixture was concentrated to a small volume, treated with ethyl acetate (200 ml) and the mixture washed with an aqueous saturated potassium carbonate solution. The organic phase was dned over sodium sulfate and concentrated to dryness. The residue (1.3 g) was crystallized from 10 ml of diethyl ether and dned under vacuum at 50°C, to give 1 06 g of the product, m p 220-225°C
Example 15
4-f2-(4-(4-fluorobenzamιdo)pιpeπdιn)ethoxy1-2-ιsoproρylιdenecumaran-3-one
A suspension of 0 08 g of sodium metal in 50 ml of dry isopropanol was heated at 60°C for 30 minutes (all of the sodium had then dissolved) and 0 55 g of 4-hydroxy-2- ιsopropylιdene-cumaran-3-one (preparation 3) were added. After a further 30 minutes at reflux 1 g of 2-[4-(4-fluorobenzarmdo) pιpeπdιnyl]-l-chloroethane (example 14) was added and the reaction mixture refluxed for 4 hours. The solvent was evaporated under reduced pressure and the residue redissolved in 100 ml of methylene chlonde and washed with 50 ml of aqueous saturated potassium carbonate solution The organic phase was dned over sodium sulfate, concentrated to dryness and the residue (3 g of a red oil) punfied by silica gel chromatography (eluent chloroform/methanol 9 1) to give, after crystallization from 10 ml of diethyl ether, 0 4 g of the product, m.p 158-160°C
Example 16
3-(4-acetamιdopιpeπdιnyl)-l-chloropropane
A mixture of 4-acetamιdopιpeπdme (1.4 g; preparation 14), tnethylamine (3 56 ml) and l-bromo-3-chloropropane (1 45 ml) in 50 ml of tetrahydrofuran was refluxed overnight, then an additional 3.5 ml of tnethylamine and 1 45 ml of l-bromo-3- chloropropane were added. After a further 3 hours at reflux, the mixture was concentrated to a small volume, treated with chloroform and washed with aqueous saturated solution of potassium carbonate. The organic phase was dned over sodium sulfate, concentrated to dryness and the residue (2.3 g of a green oil) was punfied by silica gel chromatography (eluent chloroform/methanol 9 • 1) to give 0 67 g of the product, m.p. 74-77°C Example 17
4-r3-(acetamιdopιpeπdιnyl)propoxyl-2-ιsopropylιdenecumaran-3-one
A suspension of 0.07 g of sodium metal in 50 ml of dry isopropanol was heated to 60°C until all of the sodium had dissolved, then 0.47 g of 4-hydroxy-2- ιsopropylιdenecumaran-3-one (preparation 3) was added and the mixture refluxed for 30 minutes. 3-(4-acetamιdopιpendmyl)-l-chloropropane (0.6 g; example 16) was then added and the reaction mixture again refluxed for 6 hours and finally concentrated to dryness. The residue was treated with 100 ml of chloroform and washed with 50 ml of aqueous saturated potassium carbonate solution. The organic phase was dned over sodium sulfate and concentrated to dryness and the residue (1.1 g of a red oil) punfied by silica gel chromatography (eluent chloroform/methanol 9 : 1) to give, after crystallization from diethyl ether and drying under vacuum at 50°C, 0.48 g of the product, m.p. 150-153°C.
Example 18
3-(4-heptanoylamιnopιpendιn-l-yl)-l-chloropropane
A mixture of 4-heptanoylamιnopιpeπdιne (7.49 g; preparation 16), tnethylamine (9 79 ml) and l-bromo-3-chloropropane (5.38 ml) in 200 ml of dry tetrahydrofuran was refluxed for 4 hours, then a further 9.79 ml of tnethylamine and 5.38 ml of 1-bromo- 3-chloropropane were added. The reaction mixture was refluxed overnight, then concentrated to dryness, treated with 100 ml of saturated aqueous potassium carbonate solution and extracted with ethyl acetate (2x100 ml). The organic extracts were pooled, dned over sodium sulfate and concentrated to dryness to give 15 g of an oil which was punfied by silica gel chromatography (eluent chloroform/methanol 9 • 1) to give, after crystallization from 30 ml of hexane, 6.12 g of the product, m.p. 68-70°C.
Example 19
4-r3-(4-heptanoylamιnopιpendιn-l-yl)propoxy1-2-ιsopropylιdenecumaran-3-one
0.1 g of sodium metal in 50 ml of dry isopropanol was heated to 60°C until all of the sodium had dissolved, then 0.7 g of 4-hydroxy-2-ιsopropylιdenecumaran-3-one (preparation 3) was added and the mixture refluxed for 30 minutes. 3-(4- heptanoylamιnopιpendιn-l-yl)-l-chloropropane (0.7 g; example 18) was then added and the reaction mixture refluxed overnight. The mixture was then concentrated to dryness, redissolved in methylene chlonde, washed with 100 ml of saturated aqueous potassium carbonate solution, dned over sodium sulfate and concentrated to dryness. The residue (2 g) was punfied by silica gel chromatography (eluent methylene chlonde/methanol 9 : 1) to give, after crystallization from 20 ml of diethyl ether, 0.5 g of the product, m.p. 151-153°C. Example 20
4-r3-(4-(4-fluorobenzamido)piperidin-l-yl)propoxy1-2-cyclopentylidenecumaran-3- one
A mixture of 4-hydroxy-2-cyclopentylidenecumaran-3-one (0.89 g; preparation 17), 3- [4-(4-fluorobenzamido) piperidinyl]-l-chloropropane (1.23 g; example 1) and potassium carbonate (0.56 g) in 10 ml of dry dimethylformamide was heated to 60°C for 6 hours. The reaction mixture was then poured into 200 ml of water and the solid which separated recovered by filtration and purified by silica gel chromatography (eluent chloroform/methanol 9 : 1). The residue was crystallized from 20 ml of diethyl ether and dried under vacuum at 40°C, to give 0.45 g of the product, m.p. 160-162°C.
Example 21
3-(4-cvclohexylamidopiperidin-l-yl)-l-chloropropane
A mixture of 4-cyclohexylamidopiperidine (3 g; preparation 19), triethylamine (5.16 ml) and l-bromo-3-chloropropane (2.1 ml) in 100 ml of tetrahydrofuran was refluxed overnight, then a further 5.16 ml of triethylamine and 2.1 ml of l-bromo-3- chloropropane were added. The mixture was refluxed for an additional 4 hours, then concentrated to a small volume, treated with 100 ml of saturated aqueous potassium carbonate solution and extracted with 100 ml of chloroform. The organic phase was dried over sodium sulfate and concentrated to dryness and the residue (8 g) recrystallized from 50 ml of diethyl ether to give 2.43 g of the product, m.p. 152- 155°C.
Example 22
4-[3-(4-cvclohexylamidopiperidin-l-yl)propoxy]-2-isopropylidenecumaran-3-one
0.09 g of sodium metal in 50 ml of dry isopropanol was heated to 60°C until all of the sodium had dissolved, then 0.63 g of 4-hydroxy-2-isopropylidenecumaran-3-one (preparation 3) was added and the reaction mixture refluxed for 30 minutes. 3-(4- cyclohexylamidopiperidin-l-yl)-l-chloropropane (1.43 g; example 21) was then added and the mixture refluxed for an additional 5 hours, then concentrated to dryness and redissolved in 100 ml of chloroform. The resulting organic phase was washed with 50 ml of saturated aqueous potassium carbonate solution, dried over sodium sulfate and concentrated to dryness. The residue (2 g) was purified by silica gel chromatography (eluent chloroform/methanol 9 : 1) to give, after crystallization from a little ethyl acetate, 0.65 g of the product, m.p. 193-196°C.
Elem. Anal, (calcd/found %): C 70.88/67.70; H 8.24/8.22; 6.36/6.30. Example 23
According to the methods described in the previous preparations and examples, starting from the appropriate reactants, the following benzocumaranones were prepared:
4-[3-(4-nicotinamidopiperidin-l-yl)propoxy]-2-isopropylidenecumaran-3-one, m.p. 187-191°C;
4-[3-(4-(4-trifluorometanbenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 191-193°C;
4-[3-(4-(2-naphthoylamido)piperidin-l-yl)propoxy]-2-isopropylidenecumaran- 3-one, m.p. 160-162°C;
4-P.-(4r(3,4,5-trimethoxybenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 195-198°C;
4-[3-(4-(4-bromobenzamido)piperidin- 1 -yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 176-179°C;
4-[3-(4-(2-(O-phenoxy)acetamido)piperidin- 1 -yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 115-118°C;
4-[3-(4-(4-methoxybenzamido)piperidin- 1 -yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 148-151°C;
4-[3-(4-(4-cyanobenzamido)piperidin- 1 -yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 175-178°C;
4-[3-(4-(2-(3-indolyl)acetamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 196-201°C (dec);
4-[3-(4-(2-(phenyl)acetamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 139-142°C;
4-[3-(4-(2-thenoylamido)piperidin-l-yl)propoxy]-2-isopropyliderecumaran-3- one, m.p. 215-218°C;
4-[3-(4-(2-(4-fluorobenzamido)ethyl)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 151-153°C;
(E)-4-[4-(4-(4-fluorobenzamido)piperidin-l-yl)-2-butenoxy]-2- isopropylidenecumaran-3-one, m.p. 150-152°C;
(Z)-4-[4-(4-(4-fluorobenzamido)piperidin- 1 -yl)-2-butenoxy]-2- isopropylidenecumaran-3-one, m.p. 88-90°C; 4-[3-(4-(4-methylbenzamido)piperazin-l-yl)propoxy]-2- isopropylidenecumaran-3-one;
4-[3-(4-((4-fluorobenzamido)methylpiperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 175-179°C;
4- [(5-(4-(4-fluorobenzamido)piperidin- 1 -yl)penty l)oxy ]-2- isopropylidenecumaran-3-one, m.p. 135-137°C;
4-[(3-(4-4-nitrobenzamido)piperidin-l-yl)propoxy]-2-isopropylidenecumaran- 3-one, m.p. 223 -225°C;
4-[(3-(4-(2,5-dichlorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 130 -133°C;
4-[(3-(4-(4-(methylsulfonyl)benzamido)piperidin-l-yl)propoxy]-2- isopropylidene-cumaran-3-one, m.p. 220 -222°C;
4-[(3-(4-(4-methylbenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 198 -202°C;
4-[(3-(4-(4-chlorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 204 - 205°C;
4-[(4-(4-(3-bromobenzamido)piperidin-l-yl)butyl)oxy]-2- isopropylidenecumaran-3-one, m.p. 145 - 148°C;
4-[(4-(4-(4-trifluoromethylbenzamido)piperidin-l-yl)butyl)oxy]-2- isopropylidene-cumaran-3-one, m.p. 145 - 148°C;
(+)-4-[(3-(4-(4-fluorobenzamido)piperidin-l-yl)-2-hydroxyprop-l-yl)oxy]-2- isopropylidenecumaran-3-one, m.p. 207 -209°C;
4-[(3-(4-(4-acetylaminobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 243-245°C;
4-[(3-(4-(l-naphthoylamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 173-175°C;
4- [(3-(4-(3 ,4-dichlorobenzamido)piperidin- 1 -y l)propoxy ] -2- isopropylidenecumaran-3-one, m.p. 188-190°C;
4-[(3-(4-(3,5-dichlorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 203-205°C;
4-[(3-(4-(3,5-bis(trifluoromethyl)benzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 170-172°C; (S)-4-[(3-(4-(4-((2-amino-l-oxo-3-phenylpropyl)amino)piperidin-l- yl)propoxy]-2-isopropylidenecumaran-3-one dihydrochloride, m.p. 215-217°C;
4-[(3-(4-(2-(4-fluorobenzamido)ethyl)piperazin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 158-160°C;
4-[(2-(4-(2-(4-fluorobenzamido)ethyl)piperazin-lyl)ethyl)oxy]-2- isopropylidenecumaran-3-one, m.p. 103-105°C;
4-[(3-(4-(4-(methoxycarbonyl)benzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 226-228°C;
4-[(3-(4-(3-cyanobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 188-190°C;
4-[ 2-(4-(phenylacetyl)piperazin-l-yl)ethyl)oxy]-2-isopropylidenecumaran-3- one, m.p. 108-110°C;
(S)-4-[(2-(4-(2-amino-l-oxo-3-phenylpropyl)piperazin-l-yl)ethyl)oxy]-2- isopropylidenecumaran-3-one dihydrochloride, m.p. 160-163°C;
4-[(3-(4-(4-(dimethylamino)benzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 210-212°C;
4-[(3-(4-(2-bromobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 140-142°C;
4-[(3-(4-(3-chloro-4-fluorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 188-190°C;
4-[(4-(4-(3,4-dichlorobenzamido)piperidin-l-yl)butyl)oxy]-2- isopropylidenecumaran-3-one, m.p. 163-165°C;
4-[(3-(4-(3,4-difluorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 206-208°C;
4-[(3-(4-(2,3,4-trifluorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 168-170°C;
4-[(3-(4-(3-aminosulfonyl-4-chlorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 255-258°C;
4-[(3-(4-(3-bromo-4-fluorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidene-cumaran-3-one, m.p. 206-208°C;
4-[(6-(4-(4-fluorobenzamido)piperidin-l-yl)hexyl)oxy]-2- isopropylidenecumaran-3-one, m.p. 105-107°C; 4-[(3-(4-(3-aminocarbonylbenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 154-156°C;
(Z)-4-[(4-(4-(3 ,4-dichlorobenzamido)piperidin- 1 -yl)but-2-en- 1 -y l)oxy]-2- isopropylidenecumaran-3-one, m.p. 155-158°C;
(E)-4- [(4-(4-(3 ,4-dichlorobenzamido)piperidin- 1 -yl)but-2-en 1 -y l)oxy ]-2- isopropylidenecumaran-3-one, m.p. 179-181°C;
4-[(3-(4-(2,4,5-trifluorobenzamido)piperidin-l-yl)propoxy]-2- isopropylidenecumaran-3-one, m.p. 156-158°C;
4-[(2-((2-(4-(4-fluorobenzamido)piperidin-l-yl)ethyl)oxy)ethyloxy]-2- isopropylidenecumaran-3-one, m.p. 157.5-158.5°C.

Claims

1. The use of a compound of the formula (I):
Figure imgf000028_0001
wherein:
R and R' are independently hydrogen, Q-6-alkyl, styryl or C3-6-cycloalkyl or, taken together with the carbon to which they are linked, form a C3.6-cycloalkyl group; x is 0 or 1 ;
A is -(CH2)n-, -CH2CH=CHCH2-, -CH2-CH=CH-CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-, -CH2-CH2-CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-CH2-, -CH2-CH2-CH=CH-CH2-CH2-, -CH2-CH2.CH2-CH=CH-CH2-, -CH2-CHOH-CHOH-CH2-, -(CH2)q-O-(CH2)q-, or -CHrA'-CHk-, wherein q is an integer from 2 to 3 and n is an integer from 2 to 6, and A' is a Q.7-cycloalkyl group;
B is
(i) -N(R1)-(CH2)m-N(R2)-, in which m is an integer from 2 to 6, R1 is hydrogen, methyl, ethyl, propyl, or isopropyl, and R2 is Cι-6-alkyl, benzyl, phenyl, naphtyl or indanyl, unsubstituted or substituted by chlorine, bromine, iodine, fluorine, Q-β- alkyl, hydroxy, amino, carboxy, Cι. -alkoxy, Cι.4-mono- or di-alkyl amino, C - alkoxycarbonyl, mercapto, Cι-4-alkylthio; or
Figure imgf000028_0002
Figure imgf000028_0003
T is -CH2-C≡CH, -C≡CH, -(CH2)P-R3, -CH=CH-R3, -CH2-NHCO-R3, -(CH2)p-O-R3, or -CH(NH2)-CH2R3, in which p is 0 or an integer from 1 to 4, R3 is phenyl, naphthyl or biphenyl, unsubstituted or substituted by chlorine, bromine, iodine, fluorine, (Cι-6)alkyl, cyano, nitro, mono- or polyfluoroalkyl, -SO^d^alkyl, -SO2NH2, -SO2NH(Cι-4)alkyl, -SO2N[(Cj.4)alkyl]2, -CONH2, -CONH(Cι.4)alkyl, hydroxy, amino, carboxy, Cι-4-alkoxy, (Cι.4)mono- or di-alkyl amino, (Cι.4)alkoxycarbonyl, mercapto, or Cι.4-alkylthio, or is a 5- or 6-membered heterocycle which contains 1 or 2 heteroatom(s) selected from oxygen, sulfur or nitrogen and which is or is not benzocondensed, enantiomers, diastereomers and racemates of the compounds of formula I and mixtures thereof as well as pharmaceutically acceptable salts of a compound of formula in the manufacture of a medicament.for the treatment of tumors, particularly advanced solid tumors of breats, lung or colon, and metastases thereof.
2. The use as in claim 1 wherein in the compound of formula I A is -(CH2)n-, -CH2CH=CHCH2-, -CH2-CH=CH-CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-, -CH2-CH2-CH=CH-CH2-, -CH2-CH=CH-CH2-CH2-CH2-, -CH2-CH2-CH=CH-CH2-CH2-, -CH2-CH2.CH2-CH=CH-CH2-, or -CH2-CHOH-CHOH-CH2- ,
B is
(i) -N(R')-(CH2)m-N(R2)-, in which m is an integer from 2 to 6, R1 is hydrogen, methyl, ethyl, propyl, or isopropyl, and R2 is Cι-6-alkyl, benzyl, phenyl, naphtyl or indanyl, unsubstituted or substituted by chlorine, bromine, iodine, fluorine, .6- alkyl, hydroxy, amino, carboxy, .4-alkoxy, Cj. -mono- or di-alkyl amino, .4- alkoxycarbonyl, mercapto, Cι.4-alkylthio; or
Figure imgf000029_0001
T is -CH2-C≡CH, -C≡CH, -(CH2)P-R3, -CH=CH-R3, or -CH2-NHCO-R3 in which p is 0 or an integer from 1 to 4, R3 is phenyl, naphthyl or biphenyl, unsubstituted or substituted by chlorine, bromine, iodine, fluorine, (Cl-Cό)alkyl, cyano, hydroxy, amino, carboxy, Cι.4-alkoxy,
(Cj-4)mono- or di-alkyl amino, (Cι.4)alkoxycarbonyl, mercapto, or .4-alkylthio, or is a 5- or 6-membered heterocycle which contains 1 or 2 heteroatom(s) selected from oxygen, sulfur or nitrogen and which is or is not benzocondensed, and wherein R,R\ R',R2, p and x are as in claim 1
3. A compound of formula I A
Figure imgf000030_0001
(IA) wherein
R R' , A, B, T and x are as in claim 1, provided the compound of formula IA is not 4(3-(4-(4-fluorobenzamido)pipeιidin)propoxy)-2-isopropylidencumaran-3-one.
4. A compound of claim 3, wherein A is -(CH2)Q-, -CH2CH=CHCH -, or -(CH2)q-O-(CH2)q-, n is an integer from 2-6, and q is an integer from 2 to 3.
5. A compound of claim 3, wherein x is 1.
6. A compound of claim 3, wherein B is the moiety
Figure imgf000030_0002
7. A compound of claim 3, wherein T is phenyl or phenyl substituted by one or two trifluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
8. A compound of claim 3, wherein R and R' are Q.6-alkyl.
— N V- NH-
9. A compound of claim 3, wherein x is 1, and B is the moiety N —
10. A compound of claim 9, wherein R and R' are Q-6-alkyl.
11. A compound of claim 10, wherein A is -(CH )n-, CH2CH=CHCH2-, or -(CH2)q-O-(CH2)q-, n is an integer from 2-6, - and q is an integer from 2 to 3, and T is phenyl or phenyl substituted by one or two trifluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
12. A compound of claim 11, wherein R and R' are methyl.
13. A compound of claim 12, wherein A is a -(CH2)n- group and n is an integer from 2-6.
14. A compound of claim 13, wherein n is an integer from 3-4.
15. A compound of claim 14, wherein T is phenyl substituted by one or two trifluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
16. 4-(4-(4-(3 ,4-dichlorobenzamido)piperidin- 1 -y l)butoxy)-2- isopropylidenecumaran-3-one.
17. 4-(3-(4-(3-aminosulfonyl-4-chlorobenzamido)piperidin-lyl)propoxy)-2- isopropylidenecumaran-3-one.
18. A compound of claim 12, wherein A is -CH2CH=CHCH2-.
19. A compound of claim 18, wherein T is phenyl substituted by one or two trifluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
20. (E)-4-(4-(4-(3,4-dichlorobenzamido)piperidin-l-yl)-2-butenoxy)-2- isopropylidenecumaran-3-one.
21. (Z)-4-(4-(4-(3 ,4-dichlorobenzamido)piperidin- 1 -y l)-2-butenoxy )-2- isopropylidenecumaran-3-one.
22. A compound of claim 12, wherein A is -(CH2)q-O-(CH2)q- and q is an integer from 2 to 3.
23. A compound of claim 22, wherein T is phenyl substituted by one or two trifluoro, bromo, chloro, fluoro, cyano, nitro, methyl or aminosulfonyl groups.
24. 4-(4-(4-(4-fluorobenzamido)piperidin- 1 yl)ethoxyethoxy)-2- isopropylidenecumaran-3-one.
25. Pharmaceutical compositions containing a compound according to any one of claims 3 to 24 in admixture with pharmaceutical excipients and /or diluents.
26. The novel use, compounds and compositions as described hereinbefore, especially with reference to the Examples.
PCT/EP1998/004619 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents Ceased WO1999006387A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE69832184T DE69832184D1 (en) 1997-07-31 1998-07-23 O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES WITH ANTITUMORAL AND ANTIMETASTIC EFFECT
CA002296476A CA2296476A1 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
HR20000031A HRP20000031A2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
JP2000505146A JP3241711B2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
IL13419398A IL134193A0 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
AT98943771T ATE308535T1 (en) 1997-07-31 1998-07-23 O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES WITH ANTITUMORAL AND ANTIMETASTATIC EFFECTS
HU0004221A HUP0004221A2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives, their use for producing antitumor and antimetastatic medicaments and the same medicaments
EP98943771A EP1012147B1 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
KR1020007000941A KR100343067B1 (en) 1997-07-31 1998-07-23 0-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
BR9811589-8A BR9811589A (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as anti-tumor and anti-metastatic agents
AU91559/98A AU745839B2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
NO20000366A NO20000366D0 (en) 1997-07-31 2000-01-25 O-substituted hydroxycoumaranone derivatives as anti-tumor and antimetastasis agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97113190 1997-07-31
EP97113190.9 1998-04-16
EP98106946 1998-04-16
EP98106946.1 1998-04-16

Publications (2)

Publication Number Publication Date
WO1999006387A2 true WO1999006387A2 (en) 1999-02-11
WO1999006387A3 WO1999006387A3 (en) 1999-04-22

Family

ID=26145681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004619 Ceased WO1999006387A2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents

Country Status (21)

Country Link
US (1) US6200989B1 (en)
EP (1) EP1012147B1 (en)
JP (1) JP3241711B2 (en)
KR (1) KR100343067B1 (en)
AR (1) AR013374A1 (en)
AT (1) ATE308535T1 (en)
AU (1) AU745839B2 (en)
BR (1) BR9811589A (en)
CA (1) CA2296476A1 (en)
DE (1) DE69832184D1 (en)
HR (1) HRP20000031A2 (en)
HU (1) HUP0004221A2 (en)
ID (1) ID24525A (en)
IL (1) IL134193A0 (en)
MA (1) MA26528A1 (en)
NO (1) NO20000366D0 (en)
PE (1) PE106099A1 (en)
PL (1) PL338614A1 (en)
TR (1) TR200000272T2 (en)
UY (1) UY25114A1 (en)
WO (1) WO1999006387A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100387275B1 (en) * 1999-01-30 2003-06-11 로셰 디아그노스틱스 게엠베하 O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
WO2004076444A3 (en) * 2003-02-25 2004-10-28 Hoffmann La Roche Novel hydroxycoumaranone derivatives as antitumor and antimetastatic
EP2077260A4 (en) * 2006-10-27 2011-04-20 Univ Tokyo AMIDE COMPOUND OR ITS SALTS, AND BIOFILM FORMING INHIBITOR, BIOFILM AND BACTERICIDAL REMOVING AGENT, COMPRISING THE AMIDE COMPOUND OR ITS SALTS
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
WO2019118785A2 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US20190263814A1 (en) * 2016-11-14 2019-08-29 Hovione Scientia Limited Process for the Preparation of Umeclidinium Bromide
US11318133B2 (en) 2019-06-12 2022-05-03 Praxis Biotech LLC Modulators of integrated stress response pathway
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
AU2019282253A1 (en) * 2018-06-05 2020-11-26 Altos Labs, Inc. Inhibitors of integrated stress response pathway
WO2020081361A1 (en) 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
JP6611029B1 (en) * 2018-11-05 2019-11-27 プキョン ナショナル ユニバーシティ インダストリ ユニバーシティ コーポレーション ファウンデーションＰｕｋｙｏｎｇ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ High frequency ultrasonic multifocal transducer, manufacturing apparatus thereof, and manufacturing method
WO2020243120A1 (en) 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2901336A1 (en) * 1979-01-15 1980-07-24 Boehringer Mannheim Gmbh NEW ARYLETHERS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3209271A1 (en) 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim BICYCLIC PHENOLETHERS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3587711T2 (en) * 1984-08-13 1994-04-28 Biotech Australia Pty Ltd MINACTIVE.
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100387275B1 (en) * 1999-01-30 2003-06-11 로셰 디아그노스틱스 게엠베하 O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
WO2004076444A3 (en) * 2003-02-25 2004-10-28 Hoffmann La Roche Novel hydroxycoumaranone derivatives as antitumor and antimetastatic
EP2077260A4 (en) * 2006-10-27 2011-04-20 Univ Tokyo AMIDE COMPOUND OR ITS SALTS, AND BIOFILM FORMING INHIBITOR, BIOFILM AND BACTERICIDAL REMOVING AGENT, COMPRISING THE AMIDE COMPOUND OR ITS SALTS
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
US8748617B2 (en) 2006-11-07 2014-06-10 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
US9000190B2 (en) 2006-11-07 2015-04-07 University Of Tokyo Amide compound or salt thereof, biofilm inhibitor, biofilm remover and disinfectant containing the same
AU2017357653B2 (en) * 2016-11-14 2021-11-04 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
US10759801B2 (en) * 2016-11-14 2020-09-01 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
US20190263814A1 (en) * 2016-11-14 2019-08-29 Hovione Scientia Limited Process for the Preparation of Umeclidinium Bromide
US11427584B2 (en) 2016-11-14 2022-08-30 Hovione Scientia Limited Process for the preparation of umeclidinium bromide
US12357639B2 (en) 2017-09-22 2025-07-15 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
WO2019118785A2 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US11230542B2 (en) 2017-12-13 2022-01-25 Praxis Biotech LLC Inhibitors of integrated stress response pathway
EP3723762A4 (en) * 2017-12-13 2021-12-08 Praxis Biotech LLC Inhibitors of integrated stress response pathway
CN111757739A (en) * 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 Integrated Stress Response Pathway Inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11318133B2 (en) 2019-06-12 2022-05-03 Praxis Biotech LLC Modulators of integrated stress response pathway

Also Published As

Publication number Publication date
BR9811589A (en) 2000-09-19
MA26528A1 (en) 2004-12-20
HRP20000031A2 (en) 2000-10-31
TR200000272T2 (en) 2000-09-21
AR013374A1 (en) 2000-12-27
KR100343067B1 (en) 2002-07-03
IL134193A0 (en) 2001-04-30
US6200989B1 (en) 2001-03-13
JP2001512113A (en) 2001-08-21
EP1012147A2 (en) 2000-06-28
UY25114A1 (en) 2001-01-31
CA2296476A1 (en) 1999-02-11
EP1012147B1 (en) 2005-11-02
PL338614A1 (en) 2000-11-06
AU745839B2 (en) 2002-04-11
NO20000366L (en) 2000-01-25
WO1999006387A3 (en) 1999-04-22
AU9155998A (en) 1999-02-22
HUP0004221A2 (en) 2001-04-28
ATE308535T1 (en) 2005-11-15
NO20000366D0 (en) 2000-01-25
KR20010022362A (en) 2001-03-15
DE69832184D1 (en) 2005-12-08
ID24525A (en) 2000-07-20
PE106099A1 (en) 1999-11-11
JP3241711B2 (en) 2001-12-25

Similar Documents

Publication Publication Date Title
EP1012147B1 (en) O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
US9403823B2 (en) Protein kinase inhibitors
FI94130B (en) Process for the preparation of aryl and heteroarylpiperazinylcarboxamides acting on the central nervous system
JP2001505585A (en) Novel amide compounds and their use as nitric oxide synthase inhibitors
JP2006514637A (en) Substituted 3-carbonyl-1H-indol-1-ylacetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
BG107527A (en) Aminoalkyl benzoyl-benzofuran or benzothiophene derivatives, method for prerparing same as compositions containing same
EP2733144B1 (en) Novel compound having parp inhibitory activity
HU198014B (en) Process for producing antiarithmic sulfonamides and pharmaceutical compositions containing them
JPH0987282A (en) Thiazole derivatives
Ma et al. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors
CN110317137B (en) 9, 10-anthraquinone compound or pharmaceutically acceptable salt thereof and pharmaceutical application thereof
JP2009504692A (en) Novel 4-amino-thieno [3,2-c] pyridine-7-carboxylic acid amide
JPH07330777A (en) Thieno [3,2-d] pyrimidin-4-one derivative
CN116143700B (en) Phthaloxizone compounds and preparation methods and applications thereof
MXPA00000702A (en) O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
CN112341389B (en) Nitrogen-containing aromatic heterocycle substituted quinoline formamide derivative and application thereof
CN106946759B (en) 2-indolone derivative and ring-opened derivative thereof, and synthesis method and application thereof
CZ2000343A3 (en) O-substituted hydroxy coumarone derivatives functioning as antitumor and anti-metastasis agents
US6307051B1 (en) 2-alkylidene hydroxycoumaranone derivatives
CN1129591C (en) Ortho-substituted hydroxybenzofuran-3-one derivatives as antitumor and antimetastatic agents
HK1029791A (en) O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
MXPA00000960A (en) 2-alkylidene hydroxycoumaranone derivatives
EP1026165A1 (en) O-substituted Hydroxycoumaranone derivatives as antitumor and antimetastatic agents
KR20010022500A (en) Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them
JPH045288A (en) Homopiperazine compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134193

Country of ref document: IL

Ref document number: 98807830.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 502135

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 91559/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2296476

Country of ref document: CA

Ref document number: 2296476

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20000031A

Country of ref document: HR

Ref document number: PA/a/2000/000702

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998943771

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-33/00

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PV2000-343

Country of ref document: CZ

Ref document number: 2000/00272

Country of ref document: TR

Ref document number: 1020007000941

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-343

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998943771

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007000941

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1020007000941

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 91559/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998943771

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-343

Country of ref document: CZ